Around 90% of drug candidates entering clinical trials never make it to market. What if we could simulate a trial’s outcome before the first patient is enrolled? TWIN‑GPT isn’t in production yet—but it’s already challenging how trials are designed
Everyone says VR will ‘transform healthcare’… but here’s the uncomfortable part nobody wants to talk about: regulators don’t approve hype—they approve proof. And right now, VR has a lot to prove.
Pharma has spent billions building data lakes — and yet, less than 20% of that data ever turns into real business value. That’s not a technology problem. It’s a data management problem.
In 2026, most pharma leaders will still trust a Quality System designed for a world without AI… and that’s exactly how compliance failures happen.
Pharma doesn’t lose approvals because of weak science. It loses them because regulators can’t trust the AI behind it.
90% of pharma data is never used. But the 10% that is… is rewriting who wins and who loses in this industry.
